The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Viale-A trial: Should azacitidine plus venetoclax become SoC for elderly patients with ND AML?

Jun 24, 2020

During the 25th Congress of the European Hematology Association (EHA), the AML Hub spoke to Courtney DiNardo, MD Anderson Cancer Center, Houston, US, about the Viale-A trial. We asked, Should azacitidine + venetoclax become standard of care for elderly patients with newly diagnosed AML?

In the Viale-A trial, patients treated with azacitidine + venetoclax demonstrated significantly improved survival outcomes vs those who received azacitidine alone. Courtney DiNardo suggests that azacitidine + venetoclax is a clinically effective strategy that should be considered as standard of care for elderly patients with newly diagnosed AML.

Viale-A trial: Should azacitidine plus venetoclax become SoC for elderly patients with ND AML?